**Table F-3. Subgroup analysis of included randomized trials: reduction, remission, and loss of diagnosis**

| Author  Year | Intervention Groups | Subgroup Analyzed | PTSD Symptom Reduction | Remission | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Connor et al., 1999[170](#_ENREF_170)  Meltzer-Brody et al., 2000[171](#_ENREF_171) | G1: Fluoxetine  10 to 60mg/day  G2: Placebo | Individuals with specific PTSD symptoms | Meltzer-Brody et al., 2000[171](#_ENREF_171) Symptom-Specific Effects- DTS  Mean (SD)  Within-Group Mean Change (Endpoint-Baseline)  Intrusion Baseline  G1 Baseline: 17.7  G1 Post-tx: 6.7  Change: -11.0  G2 Baseline: 21.5 G2 Post-tx: 13.5  Change: -8.0  p=0.0082  Avoidance  Baseline:  G1 Baseline: 9.2  G1 Post-tx: G1: 3.0  Change: -6.2  G2 Baseline: 9.3  G2 Post-tx: 6.3  Change:-3.0  p=0.0153  Numbing  Baseline:  G1 Baseline: 22.3  G1 Post-tx: 6.2  Change: -16.1  G2 Baseline: 22.6  G2 Post-tx: 15.1  Change: -7.5  p=0.0017 | NR | NR |

| Author  Year | Intervention Groups | Subgroup Analyzed | PTSD Symptom Reduction | Remission | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Connor et al., 1999[170](#_ENREF_170)  Meltzer-Brody et al., 2000[171](#_ENREF_171)  (continued) |  |  | Hyperarousal  Baseline:  G1Baseline: 24.7  G1 Post-tx: 9.0  Change: -15.7  G2 Baseline: 26.0 G2 Post-tx: 17.3 Change: -8.7  p=0.0029  SIP Intrusion Baseline  G1 Baseline: 10.1  G1 Post-tx: 2.9  Change: 7.2  G2 Baseline: 9.6  G2 Post-tx: 5.5 Change: 4.1  p=0.0108  Avoidance Baseline:  G1 Baseline: 3.9  G1 Post-tx: 1.1  Change: 2.8  G2 Baseline: 4.1  G2 Post-tx: 2.5  Change: 1.6  p=0.0189 |  |  |

| Author  Year | Intervention Groups | Subgroup Analyzed | PTSD Symptom Reduction | Remission | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Connor et al., 1999[170](#_ENREF_170)  Meltzer-Brody et al., 2000[171](#_ENREF_171)  (continued) |  |  | Numbing G1 Baseline: 9.6  G2 Baseline: 10.2  Change: 7.1 G1Post-tx: 2.5  G2 Post-tx: 5.8 Change: 4.4  p=0.0028  Hyperarousal G1 Baseline: 10.5  G1 Post-tx: 3.6  Change: 6.9  G2 Baseline: 10.8 G2 Post-tx: 6.6 Change: 4.2  p=0.0118 |  |  |
| Davidson et al., 2001[68](#_ENREF_68) | G1: Sertraline  50 to 200 mg/day  G2: Placebo | Gender | CAPS-2 Treatment X Sex analysis was performed but was found to be not significant. | NR | NR |
| Davidson et al., 2007[166](#_ENREF_166) | G1: Tiagabine  4 to16mg/day  G2: Placebo | Gender  Length of PTSD Diagnosis | CAPS For those with PTSD, 3 yrs: Mean Change from Baseline:  G1: 39.3 (25.9), p=NR G2: 31.2 (27.9), p=NR For Women: Mean Change from Baseline:  G1: 35.0 (24.8), p=NR  G2: 22.4 (33.4), p=NR | NR | NR |

| Author  Year | Intervention Groups | Subgroup Analyzed | PTSD Symptom Reduction | Remission | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Foa et al., 1999[14](#_ENREF_14)  Zoellner et al., 1999[134](#_ENREF_134) | G1: CBT, exposure-based therapy (PE)  G2: CBT, coping skills therapy  SIT  G3: CBT-mixed  Combined treatment (PE and SIT Training)  G4: WL | Racial/ethnic minority | PSS-I, Mean (SD) African American G1 Pre-tx: 28.48 (7.82)  G1 Post- tx: 14.35 (8.78)  G1 12 mth FU: 13.43 (11.00)  G2 Pre-tx: 35.00 (8.69) G2 Post-tx: 29.20 (8.61) G2 12 mth FU: NR  Caucasian G1 Pre-tx: 30.27 (8.90)  G1 Post-tx: 11.76 (8.23)  G1 12 mth FU: 18.99 (12.30)  G2 Pre-tx: 31.90 (4.09) G2 Post-tx: 25.80 (8.63) G2 12 mth FU: NR  Main effects of treatment, p<0.001 | NR | NR |

| Author  Year | Intervention Groups | Subgroup Analyzed | PTSD Symptom Reduction | Remission | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Friedman et al., 2007[70](#_ENREF_70) | G1: Sertraline  25 to 200 mg/day  G2: Placebo | Gender  Substance Abuse History  Severity Level | CAPS-2  Trauma type  Adjusted mean Change at Endpoint (SE) Noncombat: -22.2 (4.4) Combat: -11.7 (2.4)  Main Effects, p=0.039  IES  Trauma Type  Adjusted mean Change at Endpoint (SE)  Group 1  Noncombat: -7.1 (3.7)  Combat: -9.2 (2.0)  Group 2  Noncombat: -18.7 (3.7)  Combat: -4.4 (2.1)  Gender  Adjusted mean Change at Endpoint (SE) Male G1:-9.6 (2.0)  G2: -6.5 (2.0) Female G1: -4.2 (4.3) G2: -16.5 (4.6) TX X Gender interaction, p<0.027  Pairwise comparisons, NS  Illness severity  Adjusted mean Change at Endpoint (SE): Data NR  Greater change in more severely ill  Main Effects, p=0.17 | NR | NR |

| Author  Year | Intervention Groups | Subgroup Analyzed | PTSD Symptom Reduction | Remission | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Markowitz et al., 2015[132](#_ENREF_132)  Markowitz et al., 2016[261](#_ENREF_261) | G1: PE  G2: IPT  G3: RT | Major Depression vs. No Major Depression  Trauma Type: Sexual, Physical, Interpersonal  Gender  Primary Trauma Age | CAPS  Major Depressive Subgroup vs.No Major Depressive Disorder Subgroup Difference between Pre-tx to post-tx did not differ significantly between groups p=ns  Sexual Trauma vs. No Sexual Trauma  G1 vs. G2, p = .0244  G1 vs. G3, p = 0.282  G2 vs. G3, p = 0.7742  Physical Trauma vs. No Physical Trauma  G1 vs. G2, p = 0.7244  G1 vs. G3, p = 0.5670  G2 vs. G3, p = 0.5954  Interpersonal Trauma vs. No Interpersonal Trauma  G1 vs. G2, p = 0.1326  G1 vs. G3, p = 0.3797  G2 vs. G3, p = 0.3886  Female vs. Male  G1 vs. G2, p = 0.0355  G1 vs. G3, p = 0.2394  G2 vs. G3, p = 0.6761  Primary Trauma age<18 vs. Primary Trauma >18  G1 vs. G2, p = 0.0633  G1 vs. G3, p = 0.1585  G2 vs. G3, p = 0.6217 | Remission (CAPS score <20), Major Depressive Disorder Subgroup  G1: 26%  G2: 23%  G3: 22 %  Remission (CAPS score <20), No Major Depressive Disorder Subgroup  Pre-tx to post-tx within group difference  G1: p=0.008  G2: 0=0.032  G3: NR  G1 vs. G3 Difference: p<0.05 (higher remission)  G2 vs. G3 Difference: p<0.05 (higher remission) | NR |

| Author  Year | Intervention Groups | Subgroup Analyzed | PTSD Symptom Reduction | Remission | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Marshall et al., 2001[64](#_ENREF_64) | G1: Paroxetine  20 mg/day  G2: Paroxetine  40 mg/day  G3: Placebo | Gender  Depressed vs. Nondepressed | CAPS-2 Adjusted Mean Differences (95% CI) Men G1 vs. G3: -11.7 (-23.3 to -0.1), p<0.05 G2 vs. G3:-13.4 (-24.6 to -2.2), p=0.02 Women G1 vs. G3:-13.7 (-20.4 to -6.9), p<0.001 G2 vs. G3:-11.2 (-18.0 to -4.3), p=0.002 Nondepressed G1 vs. G3:-16.8 (-23.7 to -9.8), p<0.001 G2 vs. G3:-12.7 (-19.8 to -5.6), p<0.001 Depressed G1 vs. G3: -11.0 (-20.4 to -1.7), p<0.03 G2 vs. G3: -11.8 (-20.9 to -2.7), p<0.02 | NR | NR |

| Author  Year | Intervention Groups | Subgroup Analyzed | PTSD Symptom Reduction | Remission | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Martenyi et al., 2002[61](#_ENREF_61)  Martenyi et al., 2006[173](#_ENREF_173) | G1: Fluoxetine  20 to 80 mg/day  G2: Placebo | Gender  Racial/ethnic minority  Trauma Type  Number of Traumas  Different Symptoms  Military Veterans | Martenyi et al., 2002[61](#_ENREF_61)  TOP-8  Changes from Pre-tx to Post-tx Least Square Mean, (SE), p - value Male G1: -9.8 (0.49) G2: -7.8 (0.77), p=0.026  Female G1: -10.8 (1.25) G2: -6.9 (2.54), p=0.169  White  G1: -9.8 (0.47)  G2: -7.4 (0.76)  Nonwhite  G1: -14.4 (1.09)  G2: -18.2 (2.53), p=0.156  Combat Related Yes G1: -9.4 (0.72) G2: -5.0 (1.10), p<0.001 Combat Related No G1: -10.3 (0.65) G2: -9.6 (1.05), p=0.543  Number of Traumas, One Trauma Only G1: -9.9 (0.61) G2: -9.7 (1.00), p=0.847 Number of Traumas, ≥ 2 traumas G1: -9.9 (0.74) G2: -5.1 (1.16), p<.001 | NR | NR |

| Author  Year | Intervention Groups | Subgroup Analyzed | PTSD Symptom Reduction | Remission | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Martenyi et al., 2002[61](#_ENREF_61)  Martenyi et al., 2006[173](#_ENREF_173)  (continued) |  |  | Dissociative Symptoms DES total score = 0 G1: -9.9 (0.69) G2: -4.4 (1.17), p<0.001 Dissociative Symptoms DES total score > 0 G1: -10.7 (0.55) G2: -9.8 (0.89), p=0.383  Martenyi et al., 2006[173](#_ENREF_173)  TOP-8 Mean Difference, 95% CI -3.86 (-6.12 to -1.60), p=0.001  CAPS Mean Difference, 95% CI -15.05 (-23.80 to -6.30), p<0.001 DTS Mean Difference, 95% CI -12.88 (-23.97 to -1.79), p=0.023 |  |  |
| Monson et al., 2006[1](#_ENREF_1) | G1:CBT, CPT  G2: WL | Comorbid conditions | NR | NR | Loss of PTSD Diagnosis: Endpoint: Disabled: 33% Non-disabled: 47% 1 month f/u: Disabled: 33% Non-disabled: 27% |

| Author  Year | Intervention Groups | Subgroup Analyzed | PTSD Symptom Reduction | Remission | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Mueser et al., 2008[7](#_ENREF_7) | G1: CBT-mixed  (CBT for PTSD)  G2: UC | Severity Level | CAPS  Mean (SD) Severe, CAPS > 65  G1 Pre-tx: 82.05 (14.46)  G1 Post-tx: 59.68 (29.12)  G1 3 mth FU: 57.23 (26.92)  G1 6mth FU: 62.78 (25.01)  G2 Pre-tx: 83.87 (12.45) G2 Post-tx: 79.65 (18.41) G2 3 mth FU: 74.50 (22.17) G2 6 mth FU: 74.24 (23.54)  Group effect, p=0.004  Mild/Moderate, CAPS <65  G1 Pre-tx: 54.73 (4.74)  G1 Post-tx: 40.71 (17.56)  G1 3mth FU: 49.25 (23.77)  G1 6 mth FU: 45.30 (22.73)  G2 Pre-tx:56.07 (9.16)  G2 Post-tx: 33.86 (15.40) G2 3 mth FU: 36.78 (25.83) G2 6 mth FU: 52.00 (21.93)  Group Effect, p =.77 | NR | NR |

| Author  Year | Intervention Groups | Subgroup Analyzed | PTSD Symptom Reduction | Remission | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| Resick et al., 2002[3](#_ENREF_3)  Resick et al., 2003[125](#_ENREF_125)  Resick et al., 2012[126](#_ENREF_126) | G1: CBT, CPT  G2: CBT, exposure-based therapy (PE)  G3: WL | Exposed to Child Trauma | CAPS Mean (SD) No Childhood Sexual Abuse Pre-tx: 70.6 (18.9) Post-tx: 28.0 (20.7)  9 mth FU: 10.9 (9.1)  Childhood Sexual Abuse Pre-tx: 76.8 (18.4) Post-tx: 28.4 (27.1)  9 mth FU: 33.3 (29.6)  Time effect, p=0.000  Group effect, NS  Group X Time, NS | NR | NR |
| Tucker et al., 2001[65](#_ENREF_65) | G1: Paroxetine  20 to 50mg/day  G2: Placebo | Gender | CAPS-2 Adjusted Mean Differences (95% CI),  G1 vs. G2 Men:-15.15 (-24.31 to -5.98) Women: -10.00 (-18.68 to -3.30) | NR | NR |

| Author  Year | Intervention Groups | Subgroup Analyzed | PTSD Symptom Reduction | Remission | Loss of Diagnosis |
| --- | --- | --- | --- | --- | --- |
| van der Kolk et al., 2007[47](#_ENREF_47) | G1: EMDR  G2: Fluoxetine  10 to 60 mg/day  G3: Placebo | Exposure to Child Trauma | CAPS  Mean (SD)  Child-onset G1 Post-tx: 38.36 (20.73) G1 6 mth FU: 33.00 (22.34)  G2 Post-tx: 40.20 (14.33) G2 6 mth FU: 50.43 (8.24)  G3 Post-tx: 46.57 (20.18) G3 6 mth FU: NR  Adult-onset: G1 Post-tx: 19.92 (14.64) G1 6 mth FU: 20.17 (19.36)  G2 Post-tx: 37.75 (23.69)  G2 6 mth FU:35.36 (16.76)  G3 Post-tx: 31.92(13.87)  G3 6 mth FU: NR  Onset X Treatment Effect, NS  Patients with adult-onset had greater reductions in PTSD symptoms than those with child-onset at post-tx & 6 mth; p<0.005 (ITT), p=0.02 (Completer) | Asymptomatic at Posttreatment, % Child-onset G1: 9.1 G2: 10.0 G3: 7.1  Adult-onset G1: 46.2 G2: 18.8 G3: 16.7  Asymptomatic at Followup, %  Child-onset  G1: 33.3  G2: 0.0  G3: NR  Adult-onset  G1: 75.0  G2: 0.0  G3: NR  Adult-onset more likely to achieve asymptomatic end-state function in G1 only (Chi-square, ITT)  Posttreatment, p=0.037  Followup, p=0.045 | Lost of PTSD Diagnosis at Posttreatment, %  Child-onset G1: 72.7 G2: 90.0 G3: 57.1  Adult-onset G1: 100.0 G2: 75.0 G3: 75.0  Lost of PTSD Diagnosis at Followup, %  Child-onset  G1: 88.9  G2: 42.9  G3: NR  Adult-onset  G1: 91.7  G2: 90.9  G3: NR  Adult-onset more likely to lose diagnosis in G1 only (Chi-square, ITT)  Posttreament, p=0.052  Followup, p=0.045  G2, adult-onset more likely to lose diagnosis than child-onset, p=0.036 |

CAPS = Clinician-administered PTSD Scale; CI = confidence interval; DTS = Davidson Trauma Scale; IES = Impact of Events Scale; NA = not applicable; NR= not reported; PSS-I= PTSD Symptom Scale Interview; PTSD= Post-Traumatic Stress Disorder; SD = standard deviation; SE = standard error; TOP-8 = Treatment Outcome PTSD Scale